Trial Profile
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 May 2022
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 May 2022 Primary endpoint (Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)) has been met as per the results published in the Hypertension Research
- 01 May 2022 Results published in the Hypertension Research
- 05 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.